- Home
- PMVP vs DXR Comparison
PMVP vs DXR Comparison
Compare PMVP & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | DXR |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.5M | 71.4M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PMVP | DXR |
|---|---|---|
| Price | $1.22 | $9.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 635.4K | 12.2K |
| Earning Date | 03-06-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $7.10 |
| 52 Week High | $1.88 | $14.76 |
Technical Indicators
Market Signals| Indicator | PMVP | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 24.39 |
| Support Level | $1.12 | $8.45 |
| Resistance Level | $1.26 | $9.88 |
| Average True Range (ATR) | 0.06 | 0.43 |
| MACD | -0.05 | -0.09 |
| Stochastic Oscillator | 2.33 | 4.69 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.